Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

Zerit (stavudine) Approved For First-Line Treatment of HIV in Europe PRINCETON, N.J. -- August 25, 1997 -- Bristol-Myers Squibb Company announced that Zerit(R) (stavudine), also known as d4T, received approval by the European Union for use in combination therapy in the first-line treatment of HIV, the virus that causes AIDS, in Europe. The decision was based on recent data from clinical trials using Zerit in adults and children which demonstrate that combinations that include d4T can reduce viral load, often to undetectable levels, and increase the body's infection-fighting CD4 cells. Both are proven markers of disease improvement. Bristol-Myers Squibb is one of the leading companies in the research and development of HIV treatments. In addition to Zerit, the company markets VIDEX(R) (didanosine), also known as ddI, for treating HIV. Bristol-Myers Squibb is also developing two protease inhibitors for the treatment of HIV. Zerit has been available in the U.S. since June 1994 and in Europe since May 1996, and is available in several other countries worldwide. In the U.S., Zerit is indicated for the treatment of HIV-infected patients who have received prolonged prior AZT (zidovudine) therapy. The most notable clinical toxicity of Zerit is peripheral neuropathy, which usually resolves if treatment is withdrawn. Resumption of treatment may be considered at a reduced dose. VIDEX has been on the market in the U.S. since 1991 and is available worldwide. VIDEX is indicated for the first-line treatment of HIV infection when antiretroviral therapy is warranted. The most common adverse events associated with VIDEX are diarrhea and peripheral neuropathy. Both Zerit and VIDEX are now available for the treatment of children with AIDS. Bristol-Myers Squibb is a diversified worldwide health and personal care company whose principal businesses are pharmaceuticals, consumer products, nutritional and medical devices. It is a leading maker of innovative therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders, and cancer. The company is a leader in consumer medicines, orthopaedic devices, ostomy care, wound management, nutritional supplements, infant formulas, and hair and skin products. More information on: Zerit, Bristol-Myers Squibb E-mail this page to a friend or colleague! To print, use this version